Day

October 6, 2017
Favorable Pharmacokinetic and Safety Data for SPR741 Observed at Doses Exceeding the Anticipated Phase 2 Dose Range CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced data from the Company’s Phase 1 single...

News

How it can help to give an electric shock  
17. July 2018
1,000 old skeletons to provide new knowledge about brain disorders
17. June 2018
Lundbeck Foundation’s magazine out now
1. June 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge